1. |
Johnson SR, Cordier JF, Lazor R, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J, 2010, 35(1): 14-26.
|
2. |
徐凯峰, 胡晓文, 朱元珏. 欧洲呼吸病学会淋巴管肌瘤病指南解读. 中华结核和呼吸杂志, 2010, 33(12): 884-886.
|
3. |
赵天明, 倪吉祥, 胡学华. 淋巴管平滑肌瘤病最新研究进展. 中国全科医学, 2017, 20(24): 3056-3062.
|
4. |
McCormack FX, Gupta N, Finlay GR, et al. Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. Am J Respir Crit Care Med, 2016, 194(6): 748-761.
|
5. |
胡晓文, 朱建荣, 徐凯峰. 1981 年至 2009 年中国淋巴管肌瘤病文献资料汇总分析. 中国呼吸与危重监护杂志, 2010, 9(5): 508-511.
|
6. |
张龙举, 梁毅, 钟小宁, 等. 国内三十余年肺淋巴管肌瘤病 130 例临床与病理文献复习分析. 中国全科医学, 2015, 18(3): 329-334.
|
7. |
Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A, 1995, 92(8): 3566-3570.
|
8. |
Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A, 1998, 95(2): 548-553.
|
9. |
Issaka RB, Oommen S, Gupta SK, et al. Vascular endothelial growth factors C and D induces proliferation of lymphangioleiomyomatosis cells through autocrine crosstalk with endothelium. Am J Pathol, 2009, 175(4): 1410-1420.
|
10. |
Gupta N, Finlay GA, Kotloff RM, et al. Lymphangioleiomyomatosis diagnosis and management: high-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline. Am J Respir Crit Care Med, 2017, 196(10): 1337-1348.
|
11. |
Seyama K, Kumasaka T, Souma S, et al. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol, 2006, 4(3): 143-152.
|
12. |
Young LR, Inoue Y, McCormack FX. Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med, 2008, 358(2): 199-200.
|
13. |
Young LR, Lee HS, Inoue Y, et al. Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med, 2013, 1(6): 445-452.
|
14. |
Xu KF, Zhang P, Tian X, et al. The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (LAM). Respir Med, 2013, 107(2): 263-268.
|
15. |
Glasgow CG, Avila NA, Lin JP. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest, 2009, 135(5): 1293-1300.
|
16. |
Chang WY, Cane JL, Blakey JD, et al. Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis. Respir Res, 2012, 13: 34.
|
17. |
Young LR, Vandyke R, Gulleman PM, et al. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest, 2010, 138(3): 674-681.
|
18. |
Radzikowska E, Jaguś P, Skoczylas A, et al. Role of serum vascular endothelial growth factor D in discrimination of patients with polycystic lung diseases. Pol Arch Med Wewn, 2013, 123(10): 533-538.
|
19. |
Mou Y, Ye L, Wang J, et al. Diagnostic and treatment monitoring potential of serum vascular endothelial growth factor-D in lymphangioleiomyomatosis. Lymphology, 2016, 49(3): 140-149.
|
20. |
Radzikowska E, Jaguś P, Sobiecka M, et al. Correlation of serum vascular endothelial growth factor-D concentration with clinical presentation and course of lymphangioleiomyomatosis. Respir Med, 2015, 109(11): 1469-1475.
|
21. |
McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med, 2011, 364(17): 1595-1606.
|
22. |
Taveira-DaSilva AM, Jones AM, Julien-Williams P, et al. Long-term effect of sirolimus on serum vascular endothelial growth factor D levels in patients with lymphangioleiomyomatosis. Chest, 2018, 153(1): 124-132.
|
23. |
Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell, 2010, 40(2): 310-322.
|
24. |
Goldberg HJ, Harari S, Cottin V, et al. Everolimus for the treatment of lymphangioleiomyomatosis: a phase Ⅱ study. Eur Respir J, 2015, 46(3): 783-794.
|